Control: Matching placebo (saline solution) N = 304 Stable ambulatory HF patients with ID NYHA class II or III LVEF 45% Elevated NPs Hb <15 g/dL at screening visit Study duration: Mortality Quality of life KCCQ) Hospitalisation Exercise tolerance Discontinuation due to adverse events Drug related vascular disorders Drug related gastrointestinal disorders FAIR-HF trial: Anker (Anker , Comin-colet , Filippatos , Gutzwiller , Ponikowski ) Intervention: Weekly injections of IV iron (ferric carboxymaltose) equivalent to 200 mg iron, until week 8 or week 12, depending on required iron-repletion dose. Maintenance injections every four weeks until week 24. Control: Matching placebo (saline solution) N = 461 Ambulatory HF patients with ID NYHA class II or III LVEF 40% (class II) or 45% (class III) Hb at screening between 95 - Study duration: Mortality Quality of life VAS, KCCQ) Hospitalisation Exercise tolerance Stroke Gastrointestinal disorders IRON-HF trial: Beck- da-silva (Beck-da- ) Intervention 1: Weekly infusions of IV iron (iron sucrose) equivalent to 200mg iron for 5 weeks, plus oral placebo Intervention 2: Oral iron (ferrous sulphate) 200 mg three times / day for 8 weeks, plus IV placebo (saline) Control: Placebo of both IV and oral preparations N = 23 HF outpatients with ID HF diagnosis 3 months NHYA class II-IV LVEF < 40% Hb 12g/dL and Study duration: Mortality Improvement in NYHA class (surrogate for quality of life) Study terminated due to poor recruitment IRONOUT HF trial: Lewis Intervention: Oral iron. oral iron polysaccharide 150 mg twice daily for 16 weeks Control: Matching placebo Stable HFREF outpatients with ID Mortality Permanent study drug discontinuation Adverse events Serious adverse Study reported several outcomes (peak walk test distance and Chronic Heart Failure Treating Heart Failure NICE 2018. All rights reserved. Subject to Notice of rights. 